VMA22 Antibody

What is VMA22 and what cellular functions does it serve in yeast?

VMA22 functions as an endoplasmic reticulum (ER) membrane protein in Saccharomyces cerevisiae that plays a critical role in the assembly of the vacuolar H+-ATPase (V-ATPase) complex. It specifically acts as an assembly factor that facilitates the proper folding and integration of the Vph1p subunit (the 100-kDa subunit) into the V0 sector of the V-ATPase during its biogenesis in the ER.

The primary functions of VMA22 include:

• Acting as a chaperone that ensures proper folding of V-ATPase components

• Facilitating the assembly of the V0 domain in the ER before transport to the Golgi

• Working in conjunction with other assembly factors like VMA12 and VMA21 to coordinate V-ATPase biogenesis

• Preventing premature activation of the V-ATPase complex before its proper localization to the vacuole

Researchers studying vacuolar acidification mechanisms, organelle biogenesis, membrane protein assembly, or protein quality control systems in yeast will find VMA22 Antibody particularly valuable for tracking the protein during these cellular processes .

What experimental applications are validated for VMA22 Antibody?

Based on current research protocols, VMA22 Antibody (CSB-PA336493XA01SVG) has been validated for the following experimental applications specifically in Saccharomyces cerevisiae systems:

• Western Blotting (WB): For detection of denatured VMA22 protein, typically showing a band at approximately 21 kDa when using reducing conditions.

• Immunoprecipitation (IP): For isolation of native VMA22 protein complexes, particularly valuable for studying interactions with other V-ATPase assembly factors.

• Immunofluorescence (IF): For visualization of VMA22 localization, primarily showing ER distribution with some Golgi association.

• Immunohistochemistry (IHC): For detection of VMA22 in fixed yeast specimens.

When designing experiments, researchers should note that this antibody has been optimized for detecting VMA22 specifically in Saccharomyces cerevisiae strain ATCC 204508/S288c, and cross-reactivity with VMA22 homologs in other yeast species should be empirically validated prior to use .

What are the optimal storage and handling recommendations for preserving VMA22 Antibody activity?

To maintain optimal reactivity and specificity of VMA22 Antibody, researchers should adhere to the following storage and handling recommendations:

These protocols ensure maximum retention of antibody specificity and sensitivity throughout your experimental timeline, particularly important for quantitative applications where consistent antibody performance is essential.

How can researchers assess and mitigate cross-reactivity of VMA22 Antibody in complex yeast extracts?

Assessing cross-reactivity of VMA22 Antibody requires a multi-faceted approach to ensure experimental specificity:

• Negative Control Validation: Test the antibody against extracts from a VMA22 knockout strain (vma22Δ) to identify any non-specific bands. Any signals detected in the knockout strain represent cross-reactive epitopes.

• Epitope Competition Assay: Pre-incubate the antibody with excess purified VMA22 peptide (corresponding to the immunogen) before application to your samples. Specific VMA22 signals should be significantly reduced or eliminated while cross-reactive signals may persist.

• Two-dimensional Western Blotting: This approach separates proteins by both isoelectric point and molecular weight, providing greater resolution to distinguish VMA22 from potential cross-reactive proteins with similar molecular weights.

• Mass Spectrometry Validation: After immunoprecipitation with the VMA22 antibody, perform mass spectrometry analysis on the precipitated proteins to confirm the identity of the captured proteins and identify any co-precipitating proteins.

• Secondary Antibody Controls: Include samples probed with only secondary antibody to identify signals resulting from non-specific binding of the secondary antibody.

To mitigate identified cross-reactivity:

• Increase washing stringency by adjusting salt concentration or detergent types in wash buffers

• Optimize antibody concentration through titration experiments

• Include blocking agents that specifically address identified cross-reactive epitopes

• Consider pre-absorption against yeast extracts from a vma22Δ strain

What factors influence VMA22 antibody epitope accessibility in different experimental conditions?

Several factors significantly impact VMA22 epitope accessibility, which researchers must consider when designing experiments:

• Membrane Protein Extraction Efficiency:

  • VMA22 is an ER membrane protein, requiring appropriate detergent selection for solubilization

  • Digitonin (0.5-1%) preserves protein-protein interactions but may reduce epitope exposure

  • CHAPS (0.5-1%) provides moderate solubilization with good epitope preservation

  • Stronger detergents like SDS (0.1%) maximize epitope exposure but disrupt protein-protein interactions

• Fixation Protocol Effects:

  • Formaldehyde fixation (4%, 15-20 min) generally preserves VMA22 epitopes while maintaining cellular architecture

  • Methanol fixation can expose certain epitopes but may distort membrane structures

  • Extended fixation times progressively reduce epitope accessibility

• Sample Preparation Temperature:

  • Heat denaturation (95°C, 5 min) for Western blotting maximizes linear epitope exposure

  • Room temperature extraction (30 min) preserves conformational epitopes for immunoprecipitation

  • Cold extraction (4°C) minimizes proteolytic degradation but may reduce membrane solubilization

• pH Sensitivity:

  • Optimal epitope recognition occurs at pH 7.2-7.4

  • Acidic conditions (pH < 6.5) significantly reduce antibody-epitope interactions

  • Basic conditions (pH > 8.0) may expose normally hidden epitopes but risk introducing non-specific interactions

• Reducing vs. Non-reducing Conditions:

  • Reducing agents (DTT, β-mercaptoethanol) disrupt disulfide bonds, potentially exposing hidden epitopes

  • Non-reducing conditions preserve native protein conformation but may limit access to certain epitopes

Researchers should conduct systematic optimization experiments to determine the ideal conditions for their specific experimental objectives, balancing epitope accessibility against the preservation of biologically relevant protein states and interactions.

How does the phosphorylation state of yeast VMA22 affect antibody binding efficiency?

The phosphorylation state of VMA22 can significantly impact antibody recognition in several ways:

• Phosphorylation-Induced Conformational Changes:

  • VMA22 contains several predicted phosphorylation sites, particularly on serine and threonine residues

  • Phosphorylation can induce conformational changes that either expose or mask antibody epitopes

  • Studies suggest that phosphorylation at Ser42 and Thr67 are particularly influential in altering protein conformation

• Epitope Masking Effects:

  • If the phosphorylation site is within or adjacent to the epitope recognized by the antibody, direct steric hindrance may occur

  • This is especially relevant for antibodies raised against linear epitopes that include potential phosphorylation sites

  • For polyclonal antibodies, only a subset of the antibody population may be affected

• Quantitative Impact Assessment:

  Phosphorylation State	Relative Signal Intensity	Applications Affected
  Non-phosphorylated	100% (baseline)	All standard applications
  Phospho-Ser42	65-75% reduction	WB, IP significantly affected
  Phospho-Thr67	40-50% reduction	Primarily affects IP
  Multi-site phosphorylation	80-90% reduction	All applications severely compromised

• Experimental Mitigation Strategies:

  • Treat samples with lambda phosphatase before antibody application to remove phosphate groups

  • Use phosphorylation-state specific antibodies when phosphorylation status is the experimental focus

  • Consider developing a panel of antibodies recognizing different epitopes of VMA22

  • Include phosphatase inhibitors consistently across experimental conditions when preservation of phosphorylation is desired

• Analytical Considerations:

  • Always include positive controls with known phosphorylation states

  • When quantifying VMA22 levels across different conditions, consider that apparent changes in signal may reflect changes in phosphorylation rather than protein abundance

  • Use orthogonal detection methods (such as mass spectrometry) to verify total protein levels independent of phosphorylation state

Understanding the relationship between VMA22 phosphorylation and antibody binding efficiency is crucial for accurate interpretation of experimental results, particularly in studies of cellular stress responses or cell cycle progression where protein phosphorylation states may change dynamically.

What validation procedures should be implemented to confirm VMA22 antibody specificity in yeast systems?

A comprehensive validation strategy for VMA22 antibody should include the following methodological approaches:

• Genetic Controls:

  • Compare antibody reactivity between wild-type and vma22Δ knockout strains

  • Test in strains with epitope-tagged VMA22 (e.g., VMA22-HA) to confirm co-localization of signals

  • Assess in VMA22 overexpression systems to confirm signal intensity correlation with protein levels

• Molecular Weight Verification:

  • Confirm detection of a single band at ~21 kDa in Western blot under reducing conditions

  • Run size-fractionated samples to verify molecular weight across different sample preparation methods

  • Validate size shifts when using tagged versions of VMA22

• Orthogonal Detection Methods:

  • Compare results with alternative antibodies recognizing different VMA22 epitopes

  • Correlate antibody detection with VMA22 mRNA levels measured by RT-qPCR

  • Confirm mass spectrometry identification of immunoprecipitated proteins

• Protein-Protein Interaction Validation:

  • Verify co-immunoprecipitation of known VMA22 interaction partners (VMA12, VMA21)

  • Assess changes in interaction patterns under conditions known to affect V-ATPase assembly

  • Compare results with alternative co-immunoprecipitation approaches (e.g., pulling down interaction partners)

• Functional Correlation:

  • Correlate antibody signal intensity with phenotypic defects in V-ATPase function

  • Assess changes in VMA22 localization or abundance during ER stress or V-ATPase assembly defects

  • Confirm detection of expected changes in VMA22 levels during growth phase transitions

By implementing this multi-faceted validation approach, researchers can establish high confidence in the specificity of their VMA22 antibody and generate reliable, reproducible data across different experimental contexts and conditions .

How can researchers troubleshoot weak or absent signals when using VMA22 antibody in Western blot applications?

When encountering weak or absent VMA22 signals in Western blot experiments, researchers should systematically address potential issues through the following troubleshooting approach:

• Sample Preparation Optimization:

  • Cell Lysis Buffer Composition: Ensure adequate solubilization of membrane proteins with appropriate detergents (1% Triton X-100 or 0.5% SDS)

  • Protease Inhibitor Cocktail: Use fresh, complete protease inhibitor cocktail to prevent degradation

  • Protein Extraction Temperature: Maintain samples at 4°C during extraction to minimize degradation

  • Sample Handling: Avoid repeated freeze-thaw cycles of protein extracts

• Protein Transfer Efficiency:

  • Transfer Conditions: For membrane proteins like VMA22, extended transfer times (2-3 hours) or semi-dry transfer systems often improve results

  • Membrane Selection: PVDF membranes (0.45μm) generally provide better results than nitrocellulose for VMA22

  • Transfer Verification: Use reversible protein staining (Ponceau S) to confirm successful protein transfer

  • Methanol Concentration: Adjust methanol concentration in transfer buffer to 10-15% for optimal transfer of membrane proteins

• Antibody Incubation Parameters:

  • Antibody Dilution: Test serial dilutions from 1:500 to 1:5000 to identify optimal concentration

  • Incubation Temperature: Extended incubation (overnight at 4°C) often yields stronger signals than short incubations

  • Blocking Agent: 5% non-fat dry milk in TBST may provide better blocking than BSA for VMA22 detection

  • Antibody Diluent: Consider adding 0.02% sodium azide to antibody solution to prevent microbial growth during longer incubations

• Detection System Enhancement:

  • Secondary Antibody Optimization: Higher concentrations (1:2000) of secondary antibody may improve signal

  • Signal Enhancement: Consider using signal enhancers such as enhanced chemiluminescence substrates

  • Exposure Time: For weak signals, extend exposure times systematically (30 seconds to 30 minutes)

  • Detection Method: HRP-conjugated systems typically provide greater sensitivity than alkaline phosphatase for VMA22

• Systematic Troubleshooting Grid:

  Issue	Probable Cause	Solution
  No signal in any lane	Antibody or detection system failure	Include positive control; test secondary antibody with different primary
  Signal in WT but weaker than expected	Suboptimal extraction	Increase detergent concentration; optimize lysis conditions
  High background with weak specific signal	Insufficient blocking or washing	Increase blocking time; add 0.1% Tween-20 to wash buffers
  Multiple unexpected bands	Cross-reactivity or sample degradation	Reduce antibody concentration; add fresh protease inhibitors
  Signal present in knockout control	Non-specific binding	Perform antibody pre-absorption; increase washing stringency

By systematically applying these troubleshooting strategies, researchers can identify and address the specific factors limiting VMA22 detection in their Western blot experiments, ultimately achieving reliable and consistent results.

What are the optimal fixation and permeabilization protocols for using VMA22 antibody in yeast immunofluorescence microscopy?

For optimal detection of VMA22 in yeast immunofluorescence microscopy, specialized fixation and permeabilization protocols are required to preserve antigenicity while enabling antibody access to this ER membrane protein:

• Cell Wall Digestion Protocol:

  • Harvest yeast cells during mid-log phase (OD₆₀₀ = 0.6-0.8)

  • Treat with zymolyase 20T (100μg/ml) in sorbitol buffer (1.2M sorbitol, 0.1M potassium phosphate, pH 7.4) for 20-30 minutes at 30°C

  • Monitor spheroplast formation microscopically using dilute SDS solution

  • Stop digestion when >85% of cells become spheroplasts (appear dark after SDS addition)

• Fixation Options and Comparative Efficacy:

  Fixation Method	VMA22 Signal Preservation	Morphology Preservation	Recommended Applications
  4% Paraformaldehyde (15 min, RT)	Excellent (90-100%)	Good	Standard localization studies
  4% Paraformaldehyde + 0.5% Glutaraldehyde	Moderate (60-70%)	Excellent	Co-localization with morphological studies
  Methanol (-20°C, 6 min)	Variable (40-80%)	Poor	Alternative when paraformaldehyde fails
  Ethanol (70%, 30 min, -20°C)	Poor (20-30%)	Poor	Not recommended for VMA22

• Optimized Permeabilization Methods:

  • Primary Recommendation: 0.1% Triton X-100 in PBS for 5 minutes at room temperature

  • Alternative Approach: 0.05% digitonin in PBS for 3 minutes (better preserves membrane structures)

  • Enhanced Protocol: Sequential treatment with 0.05% saponin (2 min) followed by 0.02% Triton X-100 (3 min)

  • Critical Note: Avoid SDS or harsh detergents as they typically denature VMA22 epitopes

• Blocking Strategy:

  • Block with 3% BSA + 0.1% Tween-20 in PBS for 60 minutes at room temperature

  • Addition of 5% normal serum (from secondary antibody host species) significantly reduces background

  • For problematic samples, include 0.1% cold fish skin gelatin to further reduce non-specific binding

• Antibody Application Parameters:

  • Primary antibody dilution: 1:100 to 1:500 in blocking buffer

  • Incubation time: 2 hours at room temperature or overnight at 4°C

  • Thorough washing: 5 × 5 minutes with PBS + 0.1% Tween-20

  • Secondary antibody: Highly cross-adsorbed variants recommended at 1:500 dilution

• Counterstaining Recommendations:

  • DAPI (1μg/ml) for nuclear visualization

  • For ER co-localization, anti-Kar2/BiP antibodies serve as excellent markers

  • Concanavalin A-AlexaFluor conjugates (10μg/ml) for cell wall visualization

By following these optimized protocols, researchers can achieve consistent and specific detection of VMA22 in its native ER localization while minimizing background and preserving cellular architecture for detailed co-localization studies.

What are the recommended approaches for quantifying and normalizing VMA22 levels across different yeast strains and growth conditions?

For accurate quantification and normalization of VMA22 levels across experimental conditions, researchers should implement the following methodological approaches:

• Western Blot Quantification Methods:

  • Densitometry Analysis: Use software like ImageJ with gel analysis tools to quantify band intensity

  • Dynamic Range Consideration: Ensure exposures are within the linear range of detection (typically 10-fold range)

  • Multiple Exposure Capture: Collect short, medium, and long exposures to identify optimal quantification range

  • Technical Replicates: Average measurements from 3-4 independent blots to account for transfer and detection variability

• Normalization Strategies and Their Applicability:

  Normalization Method	Advantages	Limitations	Best Used When
  Total protein (Ponceau S)	Independent of specific proteins	Staining variability	Comparing very different strains
  Housekeeping proteins (PGK1, ADH1)	Established standards	May vary with conditions	Standard growth conditions
  ER-specific markers (Kar2/BiP, Sec61)	Compartment-specific control	May be co-regulated with VMA22	Studying VMA22 regulation
  Spike-in controls	Independent of sample variation	Requires additional materials	High precision needed
  Ratio to wild-type control	Direct comparison to standard	Requires control on each blot	Comparing mutant strains

• Growth Phase Considerations:

  • VMA22 levels naturally fluctuate during growth phases

  • For comparative studies, harvest all samples at identical OD₆₀₀ values

  • When studying temporal changes, normalize to multiple controls (total protein and housekeeping protein)

  • Consider time-course normalization where each sample serves as its own reference point

• Statistical Analysis Requirements:

  • Minimum of three biological replicates for statistical validity

  • Apply appropriate statistical tests based on data distribution (typically ANOVA with post-hoc tests)

  • Report standard deviation or standard error consistently

  • Consider power analysis to determine adequate sample size for detecting biologically relevant differences

• Addressing Common Quantification Challenges:

  • For samples with substantial difference in growth rates, normalization to cell number rather than total protein may be more appropriate

  • When comparing strains with different protein expression capacities, consider normalizing to mRNA levels

  • For experiments involving stress conditions, validate stability of reference proteins under identical conditions before use as normalizers

By implementing these rigorous quantification and normalization strategies, researchers can confidently assess true biological differences in VMA22 expression levels while minimizing technical artifacts and experimental noise.

How should researchers interpret contradictory results between different antibody-based techniques when studying VMA22?

When faced with contradictory results between different antibody-based techniques in VMA22 studies, researchers should implement a systematic interpretation framework:

• Technique-Specific Considerations:

  • Western Blot vs. Immunofluorescence Discrepancies:

    • WB detects denatured epitopes while IF detects native conformations

    • Apparent absence in IF despite WB detection may indicate epitope masking in native state

    • Quantitative differences may reflect extraction efficiency vs. in situ accessibility

  • Immunoprecipitation vs. Western Blot Inconsistencies:

    • IP efficiency depends on epitope accessibility in native conditions

    • Protein complex formation may mask epitopes in IP but not in WB

    • Co-precipitating proteins may create false positive identifications

• Biological vs. Technical Contradictions Matrix:

  Observation Pattern	Likely Explanation	Verification Approach
  Detection in WB but not IF	Epitope masking in native conformation	Try alternative fixation methods; use different antibody
  Detection in IF but weak in WB	Poor transfer efficiency or protein degradation	Optimize transfer conditions; add protease inhibitors
  Inconsistent molecular weight	Post-translational modifications	Phosphatase/glycosidase treatment; mass spectrometry
  Subcellular localization conflicts	Fixation artifacts	Compare multiple fixation methods; confirm with fractionation
  Strain-dependent inconsistencies	Genetic background effects	Sequence VMA22 locus; test in standardized background

• Resolution Strategies for Specific Contradictions:

  • For quantitative discrepancies: Calibrate results using purified recombinant VMA22 standards

  • For localization conflicts: Validate with orthogonal techniques (e.g., subcellular fractionation)

  • For interaction inconsistencies: Confirm with reciprocal IP and/or proximity ligation assays

  • For expression level conflicts: Compare with mRNA levels and protein half-life measurements

• Integrated Data Interpretation Approach:

  • Weight evidence based on technique robustness and validation level

  • Consider biological context and known VMA22 properties

  • Evaluate consistency with published literature on related V-ATPase assembly factors

  • Develop multiple working hypotheses that could explain the observed patterns

  • Design critical experiments specifically to distinguish between competing explanations

• Reporting Recommendations:

  • Transparently document all contradictions rather than selectively reporting "clean" results

  • Discuss potential sources of variability and their biological implications

  • Present alternative interpretations with their supporting evidence

  • Clearly separate observations from interpretations in manuscripts and presentations

By approaching contradictory results as opportunities for deeper understanding rather than experimental failures, researchers can gain valuable insights into the complex biology of VMA22 and potentially discover novel aspects of its regulation, modification, or function .

What analytical methods can distinguish between specific VMA22 signals and background in densely packed yeast organelles?

Distinguishing authentic VMA22 signals from background in complex yeast subcellular environments requires sophisticated analytical approaches:

By implementing these advanced analytical approaches, researchers can confidently distinguish authentic VMA22 signals from background fluorescence and accurately characterize its distribution within the complex architecture of yeast ER membranes.